#] #] ********************* #] "$d_webRawe"'economics, markets/Pharma/0_Oncolytics notes.txt' www.BillHowell.ca 02Jun2020 initial To view this file - use a text editor (not word processor) constant width font (eg courrier 10), tab - 3 spaces http://www.adlainortye.com/en_product.php Hangzhou Economic & Technological Development Area, 310018, P.R.China (near Shanghai?) Adlai Nortye pelareorep breast cancer, done Phase 2, Chinese approval for Phase 3 (see below) Japanese Oncolys https://www.oncolys.com/en/ https://www.oncolys.com/en/pipeline/ maybe Pfizer Ibrance in future? 11Jun2020 Chugai 50 GYen deal with Oncolys China - 10 oncolytic viruses Incyte, triple negative Breast Cancer Trial 25Jun2020 anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) Adlai Nortye pelareorep breast cancer, done Phase 2, Chinese approval for Phase 3 48************************************************48 24************************24 # Table of Contents, generated by : # $ grep "^#]" "$d_webRawe"'economics, markets/Pharma/0_Oncolytics notes.txt' | sed 's/^#\]/ /' ********************* "$d_webRawe"'economics, markets/Pharma/0_Oncolytics notes.txt' 02Feb2022 Investor Presentation February 2022 17Jan2022 recent ONC uptick 11Mar2021 ImmunityBio.com 06Dec2020 LMNL Liminal - what do they do? 06Dec2020 TD WaterHouse - Oncolytics Biotechnology Industry Peers 06Aug2020 StockTwits: Adlai Nortye is going to start IPO process this Month 16Jul2020 Reneejordan001: Roche is snapping up Blueprints's cancer drug for 1.74B 26Jun2020 Viralytics is an indirect wholly owned subsidiary of Merck & Co 25Jun2020 Cancer Immunotherapy Gets Boost from Newly Engineered Nanoparticles 17Jun2020 comparison Oncolytics versus competitors' oncolytic viruses 16Jun2020 ONC entered into an at-the-market (ATM) equity offering sales agreement with Canaccord 15Jun2020 Pelareorep in combination with Merck’s (MRK) Keytruda in Advanced Pancreatic Adenocarcinoma 14Jun2020 StckTwits: Beejay78 - CLDX, GLTA, VSTM, APHA; JoeNYY - sold@loss INPX IBIO CJJD NERV ONCY CTXR 12Jun2020 www.adlainortye.com 11Jun2020 Royalty model of ONCY valuation 02Jun2020 Hillarious blog banter previous day, today & yesterday 24************************24 08********08 #] 02Feb2022 Investor Presentation February 2022 "$d_webRawe"'economics, markets/Pharma/220202 Oncolytics Biotech Corporate Presentation February.pdf' Investor Presentation February 2022 Established collaborations with industry leaders evaluate pelareorep-ICI combinations Clinical collaborators include Pfizer, Merck Serono, Roche, Incyte, and Bristol-Myers Squibb 13 table of Big arma and paeorep-pharmDrug combos 08********08 #] 17Jan2022 recent ONC uptick +-----+ Hypster article : https://chicagotoday.news/world-nation/this-under-the-radar-biotech-stocks-latest-move-could-be-2022s-best-play-usa-news-group/ Radar Biotech Stock’s Latest Move Could Be 2022’s Best Play – USA News Group enero 16, 2022 ... EXAMPLES OF A CAR-T BUYING SPREE Novartis acquired CAR-T developer Endocyte for $2.1 billion,[4] then gene therapy biotech company AveXis for $8.7 billion.[5] Gilead Sciences acquired KitePharma and its lead CAR-T candidate for nearly $12 billion.[6] Celgene acquired CAR-T development pioneers Juno Therapeutics for ~$9 billion.[7] Bristol Myers Squibb went on to acquire Celgene for a whopping $74 billion.[8] Honorable Mention: Amgen acquired teneobio and its antibody tech for $900 million, which after hitting milestones could be worth up to $1.6 billion.[9] Sanofi acquired Tidal Therapeutics and its novel approach to CAR-T for $470 million.[10] 10 IMPORTANT POINTS TO REMEMBER FOR Oncolytics Biotech Inc. NASDAQ:(ONCY)(TSX:ONC) Oncolytics Biotech is developing a pair of treatments in two of the fastest growing segments in oncology, with a CAR-T market projected to be worth $6.1 billion by 2030 and an immunotherapy market projected to be worth $56.5 billion by 2025. Working towards a combination with their flagship drug pelareorep with two immune checkpoint inhibitor giants expected to be worth a combined $17 billion by 2024. 5 ongoing combination studies with major pharmaceutical companies including Pfizer, Merck, Merck KGaA, Bristol-Myers Squibb, Incyte and Roche. Product has already demonstrated it can double the survivability rate of women with hormone-receptor positive, metastatic breast cancer. Manufacturing agreement in place with Merck KGaA. Potential combination with popular and successful drugs already on the market, such as with Bavencio®, Keytruda®, Opdive® and Tecentriq®, which together in 2020 combined for roughly $24.5 billion in sales. First in class, safe and well-tolerated, intravenously delivered immune-oncolytic virus (IOV) that selectively infects cancer cells, causing innate and adaptive immune responses. Identified a biomarker that can determine whether a patient is viable for treatment within 3 weeks. Successful partnership with Adlai Nortye in China, Hong Kong, Macau, Singapore, South Korea and Taiwan, with upfront and milestone payments of up to $86.6 million, with $65 million tied to potential development expansion. Experienced leadership spanning oncology research, drug development, and other medical fields. Lastly, for an extremely in-depth overview on what CAR T is and how it works, please watch this video located here: https://www.youtube.com/watch?v=gmjLSeAXAmw 08********08 #] 11Mar2021 ImmunityBio.com From ONCY stocktwits blog https://www.tradingview.com/symbols/NASDAQ-IBRX/ ImmunityBio.com 08********08 #] 06Dec2020 LMNL Liminal - what do they do? sjmstables Bullish 1m $LMNL Here’s Breakdown of Shares: 29.39M Direct Ownership— 19.88 M Institutional: 6.77M Mural: 556 shares lol Total shares Non Retail 26.65M Retail 2.735 M Retail Shorts: 378.77K If this gets news Off to the races!!! Retail is sick- so low I sure wouldn’t want to short this one - slightest amount of news!! The interesting thing is Thomvest Asset Management direct position - riding a lot on this Plus Nov 4.75 shares bought by salf and 5.50 5 year warrants If this hits- it’s gone I wonder if take over candidate? Conference call suggests looking for strategic partner Very Interesting Any other input welcomed! 08********08 #] 06Dec2020 TD WaterHouse - Oncolytics Biotechnology Industry Peers Industry Peers Overview Table Company sortable Market Cap sortable P/E Ratio (TTM) sortable EPS Growth (5yr) sortable Canada ONC Oncolytics Biotech Inc 221.7M Canada MDNA Medicenna Therapeutics Corp 241.7M Canada RVX Resverlogix Corp 208.2M 1.4x Canada TRP Field Trip Health Ltd 164.1M Canada TMD Titan Medical Inc 127.4M 123.0x Canada LXG Lexagene Holdings Inc 88.6M As of 2020-12-06 Howell: Market cap 221 M$ but file:///media/bill/PROJECTS/Investments/Oncolytics/Top%2075%20Immunotherapy%20startups.html says funding 24M$ - must mean cash on hand, maybe net of liabilities? Options : none for ONC Try ONCY : no options? TD is useless?! ******** #] 06Aug2020 StockTwits: Adlai Nortye is going to start IPO process this Month +--+ PatientIfYouBelieve Bullish 8/5/20, 05:37 PM $ONCY There is a saying that Adlai Nortye is going to start IPO process this Month. This will definitely speed up Pelareorep to the market. Article is here (you'll need to use Google Chrome to translate it into English): med.sina.cn/article_detail_... https://med.sina.cn/article_detail_110_1_86721.html "According to sources, Hangzhou-based Arnold Pharma has completed a Series C financing of about US$100 million, and may start the IPO process in August this year." +--+ longjon2020 8/5/20, 02:34 PM $ONCY I wonder you know ONCY is expanding its portfolio! --- Intellectual Property At the end of the second quarter of 2020, we had been issued over 396 patents including 49 US and 19 Canadian patents as well as issuances in other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028. Our patent portfolio also includes methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus. ******** #] 16Jul2020 Reneejordan001: Roche is snapping up Blueprints's cancer drug for 1.74B +-----+ https://stocktwits.com/message/227573409 Reneejordan001 7/14/20, 06:38 AM $ONCY Roche is snapping up Blueprints's cancer drug for 1.74B. Perhaps, Roche isn't our suitor. Time will tell. https://xconomy.com/boston/2020/07/14/roche-blueprint-medicines-team-up-again-in-775m-ret-cancer-drug-pact/ Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact frank Vinluan, July 14th, 2020 A Blueprint Medicines cancer drug candidate currently under FDA review will have the marketing muscle of Roche behind it if it wins regulatory approval. The two companies are partnering on the drug, pralsetinib, a targeted cancer therapy developed for lung and thyroid cancers characterized by abnormalities in a gene called RET. According to deal terms announced Tuesday, the companies will jointly commercialize the pill in the US. Roche gains rights to sell the drug globally, except for China. The Swiss pharmaceutical giant agreed to pay Cambridge, MA-based Blueprint (NASDAQ: BPMC) $675 million up front for those rights. It’s also making a $100 million equity investment in its partner at $96.57 per share, a nearly 26 percent premium to Monday’s closing stock price. If the Blueprint drug achieves development, regulatory, and sales-based milestones, the biotech could earn up to $927 million more. Those milestones also cover any next-generation RET-targeting drug developed under the partnership. The collaboration “fundamentally changes the trajectory of both pralsetinib and Blueprint Medicines,” CEO Jeff Albers said on a Tuesday conference call. +--+ https://www.business-standard.com/article/international/cancer-drug-roche-blueprint-ink-1-7-bn-deal-after-gene-testing-advances-120071400706_1.html Cancer drug: Roche, Blueprint ink $1.7-bn deal after gene testing advances US company Blueprint, which has been working with Roche since 2016, could also receive up to $927 million in milestone payments, plus royalties on sales outside the United States Reuters | Zurich Last Updated at July 14, 2020 14:51 IST Roche has struck a $1.7 billion cancer drug pact with Blueprint Medicines, it said on Tuesday, as advances in genetic testing for rare mutations drive lucrative deals for expensive treatments. The Swiss drugmaker will pay $675 million in cash and make a $100 million equity investment in Blueprint for rights to pralsetinib, which could gain US approval against so-called RET-altered non-small cell lung cancer in November. US company Blueprint, which has been working with Roche since 2016, could also receive up to $927 million in milestone payments, plus royalties on sales outside the United States, Roche said in a statement. Mutations to the RET gene can drive tumour growth, but given that such genetic changes occur in only a fraction of patients with lung or thyroid cancer, genetic testing is key to prescribing the most beneficial drugs. Roche's diagnostics division is key to a deal that will enable the company to expand on a portfolio of medicines such as Alecensa and Rozlytrek, which require testing to determine which patients will benefit. "We will leverage our global reach and expertise in oncology, as well as our capabilities in diagnostics," said James Sabry, Roche's head of partnerships. Beyond lung cancer, Blueprint has also submitted pralsetinib to the US Food and Drug Administration (FDA) for treating advanced RET mutant and RET fusion-positive thyroid cancers. Roche and Blueprint are not alone in combining sophisticated diagnostics with niche drugs. Eli Lilly and Co and German drugmaker Bayer's Vitrakvi also targets tumours with a rare mutations identified by testing. Novartis and Incyte, meanwhile, won approval this year for lung cancer drug Tabrecta, which also requires genetic testing. Both Tabrecta and Vitrakvi rely on a diagnostic test from Roche's Foundation Medicine diagnostics unit. Though such gene mutations affect relatively few patients, the companies aim to turn their medicines into blockbusters by commanding prices running into the tens of thousands of dollars per month. Tabrecta costs $18,000 a month, Roche's Rozlytrek is priced similarly and Vitrakvi lists at $32,800 a month. ******** #] 26Jun2020 Viralytics is an indirect wholly owned subsidiary of Merck & Co https://www.viralytics.com Viralytics is an indirect wholly owned subsidiary of Merck & Co., Inc. (known as MSD outside the US and Canada). It is focused on the development and commercialisation of oncolytic immunotherapies that harness the power of specific viruses to preferentially infect and kill cancer cells. On 20th June 2018 Merck Sharpe and Dohme (Holdings) Pty Ltd (MSD) acquired 100% of the issued shares in Viralytics for $1.75 per share. Our lead product candidate is CAVATAK®, a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CAVATAK is being evaluated in multiple clinical trials in various combinations and modes of administration against a range of cancer indications. CAVATAK binds to specific receptor proteins highly expressed on a range of cancer cell types, and acts to destroy local as well as metastatic tumour cells. This is achieved through cell lysis and the potential generation of a specific immune response against the cancer cells. Our lead product candidate is CAVATAK®, a proprietary formulation of the common cold Coxsackievirus Type A21 (CVA21). CAVATAK is being evaluated in multiple clinical trials in various combinations and modes of administration against a range of cancer indications. CAVATAK binds to specific receptor proteins highly expressed on a range of cancer cell types, and acts to destroy local as well as metastatic tumour cells. This is achieved through cell lysis and the potential generation of a specific immune response against the cancer cells. Our other oncolytic viruses : Viralytics has investigated a range of Coxsackievirus oncolytic immunotherapeutics for cancer treatment due their targeted oncolytic activity. Viralytics holds the intellectual property rights to 5 Coxsackieviruses including CVA13, 15, 18 and 21 (CAVATAK®) and Echovirus 1 (EVATAKTM). EVATAK™ is an ECHOvirus – ECHO is an acronym for ‘enteric cytopathic human orphan’. Orphan was used to describe the virus as it is not linked to any human disease, and hence as oncolytic immunotherapy is not expected to result in side effects of any significance. EVATAKTM binds specifically to the integrin α2β1 (alpha 2 beta 1) receptor. This receptor is found in high levels on ovarian, prostate and gastric cancer cells and preclinical studies have shown that EVATAKTM destroys these cancer cells and so has the potential to be a useful therapeutic for these cancers. While all these viruses have been assessed in preclinical studies the Coxsackievirus (CVA21) demonstrated most potential and as such became Viralytics Lead Product for clinical development. Billdeep 02:29 AM $ONCY This is the battlefront for Oncolytics Biotech's pelareorep. The company's treatment has the potential to increase the percentage of patients who respond to checkpoint inhibitors. To prove out its concept, the treatment is being studied for potential combination with other treatments including Opdivo® from Bristol-Myers Squibb Company, Roche's Tecentriq®, Pfizer's and Merck's KGaA's Bavencio®, as well as Keytruda ® from Merck & Co. Inc. ***** #] 25Jun2020 Cancer Immunotherapy Gets Boost from Newly Engineered Nanoparticles +-----+ https://www.prnewswire.com/news-releases/cancer-immunotherapy-gets-boost-from-newly-engineered-nanoparticles-301083411.html Cancer Immunotherapy Gets Boost from Newly Engineered Nanoparticles FN Media Group Presents USA News Group News Commentary News provided by USA News Group Jun 25, 2020, 10:30 ET LOS ANGELES, June 25, 2020 /PRNewswire/ -- USA News Group – In a major step forward, engineers from MIT have designed nanoparticles that stimulate the immune system, helping it to attack tumors. This could contribute significantly to other immunotherapy approaches now under development. Many biotech companies working in the field of treatment of cancer are developing new and novel therapies that could potentially benefit from this new approach including Roche Holding AG (OTCQX: RHHBY), Xynomic Pharmaceuticals Holdings, Inc. (OTCPK: XYNO) and Can-Fite Biopharma Ltd. (NYSE: CANF). Immunotherapies are the latest vanguard in the battle against many forms of cancer. This promising strategy is designed to treat cancer by stimulating the body's own immune system to attack tumors. However, tumors are very good at suppressing the immune system and becoming invisible to the immune system, so these types of treatments don't work for all patients. It is anticipated that the new therapies may transition to a lead cancer treatment in the near future. An emerging therapy discovery company on this path to providing solutions is Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC). Oncolytics is a development stage biotech company working on an immuno-oncology virus known as pelareorep. Pelareorep is a safe and well-tolerated drug that bolsters the power of T-cells fighting cancer. +-----+ https://stocktwits.com/symbol/ONCY aaron03 Bullish 06:32 AM $ONCY Just a recap for those who are new to $ONCY. We are currently involved with 5 major pharmaceutical companies. Roche, Merck, Pfizer, Bristol-Myers Squibb, and now Incyte From an outsider's perspective, one has to wonder why these companies are wanting to work with $ONCY. To me, they see potential in pelareorep. Its proven to be effective. I don't think they would waste their time being involved with $ONCY. Or doing a token study/trial. Adlai Nortye's partnership with $ONCY ($86.6 million upfront and milestone payment) is chump change for these 5 companies. I see a partnership in the future with one of these companies...something around $250 million in upfront and milestone payment. And eventually a buyout. +-----+ https://newsfilter.io/a/8987dce08783031a6d3e4649fe8da0f3 SAN DIEGO and CALGARY, Alberta, June 25, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced a new investigator-sponsored triple-negative breast cancer (TNBC) study to be managed by Rutgers Cancer Institute of New Jersey. The phase 2 trial, known as IRENE, will investigate the use of pelareorep in combination with Incyte's anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) in patients with unresectable locally advanced or metastatic TNBC. ******** #] 17Jun2020 comparison Oncolytics versus competitors' oncolytic viruses +-----+ https://www.benzinga.com/general/biotech/20/06/16261362/the-daily-biotech-pulse-glaxosmithkline-ideaya-strike-oncology-partnership-decision-day-for-merck GlaxoSmithKline Announces Strategic Partnership With IDEAYA In Synthetic Lethality GlaxoSmithKline plc GSK 1.26% and Ideaya Biosciences Inc IDYA 44.63% announced a strategic partnership in synthetic lethality, an emerging field in oncology, which included the latter's synthetic lethality programs MAT2A, Pol Theta and Werner Helicase. Both these programs are to reach clinical trials within the next three years, the companies said. According to the agreement, IDEAYA is to lead the MAT2A program through early clinical development and meet all costs before GlaxoSmithKline exercises options. Thereafter, IDEAYA will contribute 20% of the global development costs. In return, IDEAYA will receive a 50% U.S. profit share and ex-U.S. royalties for the MAT2A and Werner Helicase programs. In premarket trading Tuesday, GlaxoSmithKline shares were rising 1.69% to $41.41 and IDEAYA was rallying 101.12% to $18. See also: The Week Ahead In Biotech: FDA Decisions In The Cards For Merck, Epizyme, Evoke And Ultragenyx +-----+ https://d1io3yog0oux5.cloudfront.net/_d4c3d5008da1a96fbe2eb375fcc24f8e/oncolyticsbiotech/db/300/2426/pdf/5.08.20+-+Corporate+Presentation.pdf slide #5 - comparison Oncolytics versus competitors' oncolytic viruses Pelareorep & Competitive Advantages: dsRNA5 Other OV’s Intratumoral Delivery •Specialized delivery •Variable dose •Assured delivery to tumor Armed/Modified Virus •Customized handling (changes to standard of practice) •Biosafety Level 3 Pelareorep Intravenous Delivery •Ease of delivery •Standard dose •Accesses both primary and metastatic disease Unarmed/Unmodified Virus •No change to standard practice •Biosafety Level 2 Biomarkers •T cell clonality (measure by TCR Sequencing) •CEACAM6 (measured by immunostaining) •Predictive and prognostic Slide #28 Pharma’s Growing Interest in Oncolytic Viruses competitors' oncolytic viruses : 4 acquisitions, 3 partnerships, nothing for Oncolytics Pharma has realized the importance of oncolytic viruses with checkpoint blockade Transaction Lead asset Transaction Value Amgen acquired Biovex HSV –phase 3 $425Mupfront + up to$575Min milestone payments Merck acquired Viralytics Coxsackievirus –phase 1b $394M AbbVie partnered Turnstone Biologics Rhabdovirus isolates –phase 1/2 not disclosed Bristol-Myers Squibb partnered PsiOxus Adenovirus –phase 1 $50Mupfront + up to $886Min milestone payments + royalties Merck KGgA partnered Vyriad Measles phase 1/2 Not disclosed Boehringer Ingelheim acquired VSV preclinical $245M ViraTherapeutics Jansen acquired BeneVir Undisclosed –preclinical $140Mupfront + + up to $900Min milestone payments Takeda partnered Turnstone Biologics RIVAL-01 -preclinical $120Mupfront + up to $900Min milestone payments + royalties Partnerships and acquisitions were frequently preceded by an active research collaboration between the parties Co-Development Study •Co-development agreement with Pfizer/EMD Serono to evaluate Bavencio in 2L mBC Oncolytics or Investigator Sponsored Trials (IST’s) 4 ongoing combination studies with Merck, Roche & Bristol-Myers Squibb Monetize Certain Geographies Successful partnership with Adlai Nortye •China, Hong Kong, Macau, Singapore, South Korea and Taiwan Upfront and milestone payments of up to $86.6M •$21M in milestone payments largely under Oncolytics’ control, with double-digit royalties •$65M tied to potential development expansion Catalysts & Milestones Combination With Timing AWARE-1 breast cancer study: interim biomarker data (ESMO) Roche / Tecentriq® Q2 2020 Phase 1 NCI-9603 multiple myeloma study: interim data (ASCO)* Kyprolis® Q2 2020 Phase 2 NU 18I01second line pancreatic cancer study: Merck / Keytruda® Q2 2020 interim data (ASCO)* Phase 1 WINSHIP 4398-18 multiple myeloma study: interim data (ASH)* Bristol-Myers Squibb / Opdivo® Q4 2020 Phase2 NU 18I01second line pancreatic cancer study: final data*Merck / Keytruda® Q4 2020 * Guidance provided by principal investigator Anticipated Catalysts & Milestones Combination With Initiate phase 2 BRACELET-1 study in HR+ / HER2-mBC Pfizer & Merck KGaA / Bavencio® Phase 2 BRACELET-1 metastatic breast cancer study: interim safety update Pfizer & Merck KGaA / Bavencio® AWARE-1 breast cancer study: final biomarker data Roche / Tecentriq® Complete enrollment in BRACELET-1 metastatic breast cancer study Pfizer & Merck KGaA / Bavencio® Phase 2 BRACELET-1 metastatic breast cancer study: final data Pfizer & Merck KGaA / Bavencio® ********* #] 16Jun2020 ONC entered into an at-the-market (ATM) equity offering sales agreement with Canaccord Fortun81 6/16/20, 09:26 AM $ONCY You know! Mr.Matt Coffee Micheal Moore When people invest in a Bio Company there is hope that there is an end game to the research of the initial product.. You have been at this what 20 years? Oh! I am so tired of believing. I thought when Oncy congratulated that one company on Twitter on their BO that ONCY was close and would demand much more on a superior product BUT that doesn’t seem to be the case.. Now, that seems to have been a jealous, humbled congratulations.. Moneymakers 02:46 AM $ONCY more dilution. FREE ADVICE. I warned everybody a year ago. This is a scam company. I followed this company for 10 years. More of the same. As always with Crapacord. Nobody will partner this company, nobody. The main reason is simple : The drug is not working as it s suppose to work. If anybody think I am a short, see my oldest messages taking about Oncy. I used to be an Oncy fan. LAST WARNING. More of the same. Please do your dd and homework. This is a fraud. +-----+ from https://stocktwits.com/symbol/ONCY https://newsfilter.io/a/8f0d2594a33c2d0c01742d45e383b9fb SAN DIEGO, Calif. and CALGARY, Alberta, June 15, 2020 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it has entered into an at-the-market (ATM) equity offering sales agreement with Canaccord Genuity LLC. The ATM allows the Company, at its sole discretion, to issue common shares from treasury, at prevailing market prices, with an aggregate gross sales amount of up to $40 million over the course of the next 25 months. The company has no obligation to sell any shares pursuant to the ATM. The ATM provides Oncolytics the option to efficiently tap into the financial markets as needed to support ongoing business development activities and clinical trials, while bolstering management's ability to negotiate potential business development agreements from a position of financial strength. ********* #] 15Jun2020 Pelareorep in combination with Merck’s (MRK) Keytruda in Advanced Pancreatic Adenocarcinoma +-----+ https://stocktwits.com/symbol/ONCY vk04982 Bullish 6/12/20, 11:44 PM $ONCY In November 2019, Oncolytics Biotech announced a partial response of 17.4 months from 1b REO 024 study evaluating Pelareorep in combination with Merck’s (MRK) Keytruda in Advanced Pancreatic Adenocarcinoma patients. The partial response has already exceeded the historical overall survival data in this indication. The company is now evaluating this combination regimen in the Phase 2 trial. Oncolytics Biotech expects to complete Phase 2 enrolment by mid-2020 and release final data from the trial in the second half of 2020 On January 2, Roth Capital analyst, Jonathan Aschoff reiterated the “Buy” rating and increased Oncolytics’ target price from $6.80 to $9.0. The analyst expects final data from the Phase 2 AWARE-1 breast cancer trial in the second quarter of 2020. In December 2019, Echelon Wealth Partners’ Douglas Loe reiterated “buy” rating for the stock and set target price at $8.43. +-----+ https://stocktwits.com/message/219806441 Lifetime vk04982 6/13/20, 07:22 PM $ONCY Trying to open a position here, hence sharing some of my DD,someone please vet this ? Everything looks very positive but share price does not reflect the same so concerned little bit.... Milestones & News Flow AWARE-1 breast cancer study - interim biomarker data (ESMO Breast Cancer): Q2 2020 Result : Positive - Peripheral T cell clonality emerges as potential predictive and prognostic biomarker Multiple myeloma study (NCI-9603) - interim data (ASCO)*: Q2 2020 Result : Positive - 50% Overall Response Rate and 83% Clinical Benefit Rate in patients who failed carfilzomib - T cell activation resulting in the 1st report of cytokine storm associated with tumor response in multiple myeloma · Phase 2 second-line pancreatic cancer study – interim data (ASCO)*: Q2 2020 ?? Pending Phase 2 second-line pancreatic cancer study - final data*: Q4 2020 Multiple myeloma study (Opdivo® combination) - interim data (ASH)*: Q4 2020 ?? Pending 1 8 1 Like bizango 6/13/20, 08:27 PM @vk04982 Run, run far away. Nothing but bag holders here, including me. 1 10 ringo16 6/13/20, 08:59 PM @vk04982 if results were as good as MC says, surely the company would have had some BO offers, however we still have several years to go with the Big pharma collaborations. Instead, we have got other free ride for the boys to dilute for 150.000.000 cdn. No tutes and no insider ownership other than self granted options. 1 10 Lifetime vk04982 6/13/20, 09:04 PM @ringo16 This biotech has been operating since 1998 ? 8 Canadafan14 6/13/20, 10:42 PM @vk04982 Everything you say IS TRUE Many short sellers love to talk it down. Results & further informtion is due within next few months ONC is in collaboration with Pfizer, Roche, Merck & BMS Yes has been a long time, to get to this point & some are tired off waiting. However, the analysts whom are un-biased have a $7-$9 price target for ONCY. Why is price low, becasue the short sellers like it that way. last short squeeze was December, price shot up to $4.50 from much lower than now. The $150million mentioned is a renewal of a shelf prosepctus that has been on the books for years. They are well fianced until mid 2021 4 10 Lifetime vk04982 6/13/20, 10:54 PM @Canadafan14 Thanks for your feedback. Price at the moment just does not make any sense. Major holders that have opened new positions in ONCY include Two Sigma Advisers, Lp, Creative Planning, Wedbush Securities Inc, Banco Bilbao Vizcaya Argentaria, S.a., Private Advisor Group, LLC, Advisor Group Holdings, Inc., BlackRock Inc., Fifth Third Bancorp, Bank Julius Baer & Co. Ltd, Zurich, and Cowen Prime Services LLC. - Which seems reasonably good. $150 million offering would excite me, as then something really big should be on the cards (logically) soon Will keep working on the data but this seems too good to be true to be so unappreciated. 1 8 KinkyTurtle Bearish 6/14/20, 07:07 AM @vk04982 @Canadafan14 Companies has great science and great data from past trials. If you're looking to make money, this ain't the place though. Don't get your money stuck in here for another decade. Everytime the company release good data, the stock price goes down. 10 Lifetime vk04982 6/14/20, 09:06 AM @KinkyTurtle @Canadafan14 Thanks 7 Oncyobserver Bullish 6/14/20, 12:54 PM @vk04982 One thing is true, you make money when you see the value in things before everybody else. That’s where we are at right now with ONCY. 1 8 ricjohn2 12:26 AM @ringo16 @vk04982 not looking good 10 ricjohn2 12:27 AM @vk04982 @Canadafan14 smoke and mirrors—there is reason institutions own under 2% ********* #] 14Jun2020 StckTwits: Beejay78 - CLDX, GLTA, VSTM, APHA; JoeNYY - sold@loss INPX IBIO CJJD NERV ONCY CTXR https://stocktwits.com/symbol/ONCY Beejay78 6/13/20, 03:30 AM $CLDX sold yday my 4K @ 9.05 in the Nasdaq-opening after buying it at 1.73 end of March. Thx a lot $CLDX - you have been a great ride, but too big dipping now IMO. GLTA keeping their long positions - moved on to $VSTM yday with 5k @ 1.75 and keeping my biotech positions in $ONCY from 1.40 and $ONTX from 0.33 hoping for similar rides and long-term my ‘pot-love‘ $APHA with average of 4.3 JoeNYY 6/12/20, 09:42 PM Today's trade results (I sold most of my swing holdings today due to market uncertainty,and I am also getting married tomorrow and needed to clear my mind of stocks.I have also been extremely fatigued mentally from working a full-time job and day/swing trading on the side for the last few months. It is literally like having two full-time jobs coinciding together.Coming home from an 8 hour day job to research stocks for hours and organize stock twits posts is unmanageable at least for me.I am going to be taking it easy for the next week or so to recuperate and look to limit my swing trades moving forward to around 6 or so until I can handle moving back up without becoming mentally fatigued.Will look to remain in swings longer as well I am still currently holding 3 stocks for swings until at least Monday (see my other post for current swing holdings I sold all these stocks for a loss $INPX $IBIO $CJJD $NERV $ONCY CTXR Two breakevens were HTGM and BIOL Results-$1300 realized loss ********* #] 12Jun2020 www.adlainortye.com http://www.adlainortye.com/en_product.php Hangzhou Economic & Technological Development Area, 310018, P.R.China (near Shanghai?) Adlai Nortye pelareorep breast cancer, done Phase 2, Chinese approval for Phase 3 (see below) - "Sinopep Pharmaceutical" was established in 2004. - The fund from Science and Technology Ministry in 2009. - Recognized as a “National High-tech Enterprises” in 2009. - The 11th Polypeptide Technology Application Award in 2010. - Shareholding system reform and renamed “Adlai Nortye Biopharma” in 2016. - Listed on NEEQ in Feb 21, 2017. （Stock Code：870946） - Terminated a listing on NEEQ in Mar, 2018. - Raising $53 million in Series B Round of financing in June, 2018. China Phase 3 approval : Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers and has been demonstrated to be able to escape neutralizing antibodies found in patients. Pelareorep has received Fast Track designation and Special Protocol Assessment Agreement for phase III clinical trial from FDA for the treatment of metastatic breast cancer. And we also received approvsl from the National Medical Products Administration (NMPA) of China for initiating the open-label, randomized, multicenter, global phase III clinical trial for pelareorep (AN1004) in combination with paclitaxel in patients with advanced/ metastatic breast cancer in China. Paclitaxel - Wikipedia https://en.wikipedia.org/wiki/Paclitaxel Paclitaxel (PTX), sold under the brand name Taxol among others, is a chemotherapy medication used to treat a number of types of cancer. This includes ovarian cancer, breast cancer, lung cancer, Kaposi sarcoma, cervical cancer, and pancreatic cancer. It is given by injection into a vein. There is also an albumin-bound formulation.. Common side effects include hair loss, bone marrow suppression ... Bristol-Myers Squibb trade name Taxol® Pfizer & everybody else? Paclitaxel - Phyton Biotech https://phytonbiotech.com/apis/paclitaxel/ Largest Global Supplier of Paclitaxel API via PCF® Paclitaxel (sold under trade name Taxol® by Bristol-Myers Squibb) is a very effective plant-derived chemotherapy drug used to treat breast, ovarian, lung, bladder, prostate, melanoma, esophageal, as well as other types of solid tumor cancers. Japanese Oncolys https://www.oncolys.com/en/ https://www.oncolys.com/en/pipeline/ Early detection : Telomescan OBP-401/1101 into clinical usefulness stage? Local therapy : Telomelysin esophagel, gastri/gastroesophageal junction cancer Prognosis assessment: Telomescan Systemic therapy : OBP-801 Their patent page doesn't mention Oncolytics!?!?!? 03Jun2020 report https://ssl4.eir-parts.net/doc/4588/tdnet/1844266/00.pdf Oncolys BioPharma Inc.Orphan-Drug Designation of Telomelysin for Treatment of Esophageal Cancer 7-year market exclusivity ********* #] 11Jun2020 Royalty model of ONCY valuation +-----+ Royalty model of ONCY valuation : https://www.upcounsel.com/patent-licensing-royalty-rates Examples of average royalty rates by industry are as follows: Pharma and biotech, 6 percent https://www.cnbc.com/2020/01/28/pfizer-pfe-earnings-q4-2019.html Pfizer profit misses as breast cancer drug sales fall short of estimates Published Tue, Jan 28 20206:55 AM ESTUpdated Tue, Jan 28 202010:45 AM EST Sales of breast cancer drug Ibrance, a growth driver for Pfizer, rose 13% to $1.28 billion in the quarter, but missed the consensus estimate of $1.35 billion, according to IBES data from Refinitiv. Projected sales of pelareorep : Say [Pelareorep, Ibrance] sales of double current Ibrance : 3 G$ on generous side Pelareorep gets 25% of 6% royalties on combined sales (again, VERY generous for not doing any heavy [work, financing, development]!) ONCY royalty potential = 3 G$/yr * 6% royalty * 25% ONCY share = 0.0450 G$/yr or 45 M$/yr https://www.tradingview.com/symbols/NASDAQ-ONCY/ : Market Capitalization 51.003M Enterprise Value (MRQ) 30.626M Total Shares Outstanding (MRQ) 26.358M Number of Employees 23 Number of Shareholders 196 ONCY revenue/shr/yr before any further dilution : EPS guess after full market deployment, for 10 years of patent coverage? : = 45 M$/yr / (26.358 M shares) ~= 1.71 $/yr/sh >> That's not a bad guess of the current share price, considering there have never been royalty revenues that I know of? (coming up soon as time payment of Japanes Onsolys?) Very low overhead on licensing, maybe high legal costs for patent protection etc (by Pfizer - lower royalty share of Oncolytics). Use price-Earnings ratio of 40, assuming other ESTABLISHED synergistic candidates that total 3*Pfizer Ibrance. Stock Price once established market : = 40 * 3 Pfizer included royalty drug combos * 1.71 $/yr/sh = 205 $/sh stock market price, but : - ONLY after equivalent of 3 [ONCY Pelareorep, Pfizer Ibrance] equivalents [established, selling] on the market - before mature stage of drug - potential for far higher [royalties, stock price] if many new [areas, specific drugs] combos are successful - potential for ZERO royalties if patent rights not respected or circumvented (with time, good potential for the latter). +-----+ https://stocktwits.com/symbol/ONCY xiangtaner Bullish 09:31 AM $ONCY China has about 10 oncolytic virus candidates in various clinical stages, including Adlai Nortye's pelareorep (licensed from the Canadian biotech Oncolytics in 2017) under Phase III studies treating late-stage/metastatic breast cancer. Milestone payments soon? https://www.thepharmaletter.com/in-brief/brief-today-s-china-snippets ********* #] 02Jun2020 Hillarious blog banter previous day, today & yesterday https://stocktwits.com/symbol/ONCY Howell ONC trade trade today closed day limit sell sold 3.07 day limit (~2.27) >> I dumped 1578 shares >> hilarious, one timy schmuck (me) tanks the stock with a bit-sell? >> scary shit!! xiangtaner Bullish 6m $ONCY Shorts worked really very hard on it, But hey we’re green today! Up up going forward, and especially look forward to a big surprise and short squeeze! Longs will be greatly rewarded! BMWLTWM3 52m $ONCY Volume please... abavestor Bullish 01:14 PM $ONCY let s call the management and tell them Pfizer is distributing free money hhhh Jfktang 11:50 AM $ONCY stocktwits.com/Jfktang/mess... Ulconindicator 11:40 AM $ONCY Don't be surprised if that $PFE news isn't followed up by another article stating who potential recipients of their $500 million could be. If $ONCY gets mentioned, this will pop for sure. JohnnyYeg Bullish 12:03 PM @Ulconindicator $500 million? That's the numbers they were using three years ago as valuations. Insulting today.... :) Ulconindicator 12:05 PM @JohnnyYeg watch what happens to ONCY if they even throw $50 million at them. JohnnyYeg Bullish 12:09 PM @Ulconindicator Absolutely, but we will never know IF they did make an offer of $500 million. I always harken back to Forty Seven being bought out by Gilead for $4.7 billion - hence my saying $500 million is insulting... sparty14 52m @JohnnyYeg @Ulconindicator I'd like to see an announcement with the Bracelet trial startup that Pfizer is picking up the tab! Ulconindicator 22m @sparty14 @JohnnyYeg **** Ulconindicator 21m @sparty14 @JohnnyYeg Very real possibility. I'm not sure about tomorrow lol. But if they do, this stock rips. Ulconindicator 10:57 AM $ONCY I'm maxed out on my position here. If not I'd be buying at these levels for sure. I've been the lucky recipient in the past of a bio stock going from $1.70 to $5.30 overnight on partnership/funding deals. Ulconindicator 10:52 AM $ONCY The timing of that release tells me Pfizer is stung by their P3 breast cancer failure. I'm not putting cart before horse but somehow I see $ONCY in their plans. ringo16 11:20 AM @Ulconindicator I concur this is ONCY's best card in play. Now patience. Ulconindicator 10:42 AM $ONCY Did anybody else see this? finance.yahoo.com/news/pfiz... Ulconindicator 11:29 AM Let this news cause investors to inquire who Pfizer works with and I wouldn't doubt new money comes into $ONCY. Jfktang 10:17 AM $ONCY Wizard_of_Odds 52m $ONCY $MNLO $KTOV I have a quick question for those of you have have been investing in biotech for a long time. I’m pretty new to this sector so I am not 100% sure on this but just wanted to get your perspective. So basically what I’m wondering is, How have you not yet killed yourselves? BullishDurham 50m @Wizard_of_Odds Don't have enough money left for rope. fedup2 48m @Wizard_of_Odds Stay nimble and don't get greedy! Tcal23 43m @Wizard_of_Odds well since I’m in MNlO at 1.65 I’m still up a decent amount. it’s all about perspective. CLVS on the other hand makes me want to take a bat to the face. Wizard_of_Odds 40m @Tcal23 I’m up on $MNLO too and holding on, but liquidated $KTOV last week and $ONCY today. KTOV because it was being heavily manipulated by Sabby, and ONCY only because I wanted the cash to buy $VTIQ warrants on the dip just now. But was mostly just posting as a joke because they are such weird beasts, often not even responding to great news, and rising and falling wildly on a whim. Diet 37m @Wizard_of_Odds @Tcal23 the one thing I can’t wrap my head around is the high target prices (+200-300%) but the stock going down for 5y... 😱 Any veteran biopharma investors who can share their take? Tcal23 Bullish 29m @Wizard_of_Odds it certainly is odd how the market is reacting. For example with MNLO. Peak sales are estimated around $300mil for the 2 approved drugs with good results for another blockbuster in phase 2. They have cash through 2021. How is this market cap not 2-3x this? mikespitters Bullish 14m (09:31 my time) $ONCY Patiently waiting for the next check marks. >> EndOfPhase2 -> going into phase III scamman 08:52 AM $ONCY oops someone unloaded 650 shares and knocked 6 cents off the price?????? Sergovd79 09:02 AM @scamman lol Vannabis Bullish 09:43 AM @scamman let them. more for us KinkyTurtle 10:16 AM @scamman wise people LeeCasey Bullish 08:26 AM $ONCY we are tearing down that wall! 2.33! Finally something to watch. Canadafan14 Bullish 07:57 AM $ONCY way to many bears on here today...a clear indication the price will close UP..Not down. Sorry about your luck bears, but I understand there is a presentation today with Dr prat talking about the Aware-1 trial. That will be a promotioanl type of thing and in the past has lead to price turn arounds....upwards. And not to mention recent analysts targets in the $7-$9 range. The price is simply way too low right now., Just as we have seen the price top out and retract, time to bottom out and come back up. Today...will close up. Vannabis Bullish 07:46 AM $ONCY Some angry ass bears here lmao. You obviously don’t realize how nice of a gem this stock is, this will be $6-$12. Pelareorep is a game changer for cancer treatments, and the more they test it on, the more it seems to show efficacy for treatments LeeCasey Bearish 07:42 AM $ONCY I wanna see ONCY DEEP RED! Anything but another podunk performance. Jakefromstatefarm78 07:37 AM $ONCY garbage LeeCasey Bearish 07:33 AM $ONCY taker her under $1. I’m tired of looking at this ugly performance. Maybe she can hang around delist levels again before she gets her attitude correct. naseroner 06:53 AM $HHT low float needs that one day. Holding $ADMA $ONCY and $MARK ruipereira2 Bullish 04:03 AM $ONCY how strange :) already showing a slow and steady growth on premarket...as Darwin and Freud predicted. Evolution, wants and needs. Grab to the bull. romura1 6/1/20, 11:51 PM $ONCY romura1 Bullish 6/1/20, 11:51 PM $ONCY will have good results tomorrow JoeNYY Bullish 6/1/20, 08:20 PM (Part 2) My current swing stocks I am holding until at least tomorrow (9 total stocks). Check my other post for my other swing stocks. $ABIO -Bought today at 9.25 (Severely oversold chart. Gambled a bit here as it was a falling knife but it paid off as of now. Nice AH action as well). $APDN -Bought today at 9.54 (I really like this chart and think we see 11$ in the near term). $ONCY -Bought today at 2.31 (I played this during the last drop from 2.31 to 2.51. Chart is once again sitting at support. Lets see if I can pull off something similar again). $SONN -Still holding at 4.02 from Friday (Not much to say here. It is due up for a nice pump, but I will let it go if it drops below 4$ for an extended time (1-2 days). Diet Bullish 6/1/20, 06:52 PM $ONCY @JohnnyYeg @Reneejordan001 What are we thinking? I’m holding for now, been rough days tho sparty14 Bullish 6/1/20, 05:46 PM $ONCY I wasn't lying, @Dan_Dan posted this. At the bottom it talks about a KOL call on June 2 with Dr. Prat. ruipereira2 6/1/20, 02:58 PM $ONCY @sparty14 I can’t find anything about that interview. Given compliance issues, all interviews, if $ONCY related, need to be approved and should be present on the site’s agenda. However June is cancer survival month and nothing better than give all cancer survivals worldwide a good new to cheer them up. Someone is working and fighting also with them. Above all I wish them all the best fortune. sparty14 6/1/20, 02:09 PM $ONCY all you smart bulls here, I recall seeing somewhere recently that someone from ONCY was going to be interviewed on June 2nd. Does anyone have that info? Reneejordan001 6/1/20, 01:52 PM $ONCY A nice 54k buy just before trumpbull22 6/1/20, 01:37 PM $ONCY I though I bought this thing right but no bounce! WT efff sparty14 Bullish 6/1/20, 01:33 PM $ONCY 50k just gobbled up at $2.30, need more volume though BMWLTWM3 6/1/20, 01:24 PM $ONCY FPPoS.... otisdaddy Bullish 6/1/20, 12:56 PM $ONCY Just checking but do the shorts ever lose? CLVS...EVFM...and now ONCY...sit around get good news that should blow the shorts up and the market just bleeds...seems like if you are playing from the long side you better be pretty quick in taking your profits. Seems unlikely this is going to 6 bucks unless it is a move that takes the next year or so(An investment vs betting on a binary outcome. Thoughts for a frustrated Bull? Koush 6/1/20, 12:20 PM $ONCY if all the good news and good data doesn't move this, something is wrong with this. Careful. Ulconindicator 6/1/20, 12:02 PM $ONCY People use the term manipulation. You are seeing a classic example of that today. Arbitrage. Now that big sell wall has moved down to $2.31. Someone has set that are are accumulating at lower prices. As I write this they are moving it lower. ruipereira2 Bullish 6/1/20, 11:01 AM $ONCY Today it will be stuck here and it will be a good thing. It is a sign that bears are out of steam. I will close something around 2.3 and 2.33. A sustained and slow growth in upcoming days. No major spikes here as it should be. But a sound investment. aaron03 Bullish 6/1/20, 10:03 AM $ONCY Massive wall at $2.33. If we can clear that wall...then we'll be able to proceed forward. AmzieLove 6/1/20, 09:42 AM $ONCY $FATE $MRNA Seems that there are a few companies working on "cancer vaccine(s)". What's your pick and why?ptcommunity.com/wire/severa... Darktilt85 Bullish 6/1/20, 09:32 AM $ONCY bought more just now +900 livelifenow Bullish 6/1/20, 09:16 AM $ONCY you can never let your guard down with this stock because you kow the science is good and after 20 years and its present visabilty with big pharma you may just step out for a minute and itrs gets bought out or drop FDA news . At least this is why I am not ever dropping my shares until a BO or $30. ringo16 6/1/20, 09:13 AM $ONCY Long since 2012, 1 year before the PIII H & N fiasco. It seems the stock may loose steem. Most likely no SOLTI up date until December, Panc follow up recruiting a new set of patients sometime we don´t know as the start of Bracelet-1 which depends on the COVID-19 situation. It seems no more catalysts for a while. BMWLTWM3 6/1/20, 08:56 AM $ONCY wrong direction on short volume: Short Interest Ratio (Days To Cover) - 1.5 Short Percent of Float - 5.78 % Short % Increase / Decrease - 19 % Short Interest (Shares Short) - 1,500,000 Short Interest (Shares Short) - Prior - 1,260,000 PharmD93 6/1/20, 08:54 AM $KZIA great data here and barely a move? $MBRX $ONCY $GILD ruipereira2 Bullish 6/1/20, 08:49 AM $ONCY the big volume is gone and I am waiting for some scary cat to drop its shares. It will come the 2.20 and then I am going ballistic. Feel free to join me. ruipereira2 Bullish 6/1/20, 08:47 AM $ONCY @LeeCasey I understand you but I was waiting for the bears. I just need the 2.2 and I am buying more. The next three days will be sweet. The next months will be pure sugar. I should buy some insulin stocks. LeeCasey 6/1/20, 08:45 AM $ONCY People be trading her like salty wet garbage 🗑🚬🐓 ruipereira2 6/1/20, 08:32 AM $ONCY This is almost Darwin and Freud all together. I see frighten people from the lack of news during the weekend. The pick up on Friday was a good marketing action from $ONCY . The news on Sunday were null, not negative but redirected. But, again, no news is bad news. And a better marketeer would have done wonders on Sunday. What you are seeing now is bears loosing strength. They can't push it more down because now the skin is coming out. They are "bullies" now :) BMWLTWM3 6/1/20, 08:25 AM $ONCY disappointing ! mybluc4 6/1/20, 07:59 AM $ONCY We can only hope: Provisional patent applications have been filed for these Ii-Key-SARS-2 peptides, protecting intellectual property rights for Generex and COVID-19 vaccine products based on the viral sequences with Ii-Key. Once the peptides pass Quality Assurance testing, they will be shipped to the clinical laboratories conducting the “Ex-Vivo” Human Immune System Screening Program using blood and plasma samples from patients who have recovered from COVID-19 that have already been collected and stored for the screening program. 6packerstacker Bullish 6/1/20, 07:54 AM $ONCY criminal that a legitimate company is being beaten down like this ruipereira2 Bullish 6/1/20, 07:50 AM $ONCY Bears, your time is out. Please be careful when leaving the train and how you land :) JoeNYY Bullish 6/1/20, 07:49 AM $ONCY Back in for a swing at 2.31. Last time played this from 2.31 to 2.51 ruipereira2 6/1/20, 07:47 AM $ONCY Bears, you pathetic little things. I am looking to the volume of trades and I see a big black thing coming your way. Let's see if you can handle the bull. I am just sad because i didn't get my pick at 2.20. You greedy bast... :) dynas1975 6/1/20, 07:43 AM $ONCY This just keeps going down. I had hoped it would swing back up.. painful mikespitters Bullish 6/1/20, 07:42 AM $ONCY $2.31. Catch up, ST ruipereira2 Bullish 6/1/20, 07:36 AM $ONCY Bears, don't let me down. I said 2.20 or a bit worse, if you have the power. I wan't a bigger piece of that pie. I want more stocks. Give me yours because we can all win-win. ruipereira2 Bullish 6/1/20, 07:31 AM $ONCY Today we will see a quick decline, maybe to 2.2 tops. Bears will grab on to all stocks and after 20 minutes you will see a continuous increase during the current days. Focus. Negative marketing is as strong as positive marketing that will soon come. aaron03 Bullish 6/1/20, 07:18 AM $ONCY I've seen this song and dance before. Heavy manipulation in the premarket to lower the share price down and skyrocket during normal trading hours. We'll see if that's what happens today. Any day now we should get a PR discussing the start of the BRACELET trial. ruipereira2 6/1/20, 07:07 AM $ONCY It's an open market. There are sellers and there are buyers. There are different strategies and there is marketing. There is a lot of marketing from the bears and not so much from the company. What seems it is usually the reality. This is a great stock and it will be bullish in the next months. Pretty bullish. But now, the lacking of a proper marketing strategy form the company (and their goal is assist in curing cancer and not making our profit) we are witnessing this downtrends. The bears are winning for now. But this is a secure stock for a long position. And by long I mean one month. Just stick to it and trust. Don't get intimidated. gopatzgo 6/1/20, 06:37 AM $ONCY enough already KinkyTurtle Bearish 6/1/20, 06:35 AM $ONCY looks like this is going down the drain already. :( glaucio76 6/1/20, 05:43 AM $ONCY ha, I told you.😒😒😒☠☠☠💩 Billdeep 6/1/20, 05:39 AM $ONCY Consensus Rating Oncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings. Price Target Upside/Downside According to analysts' consensus price target of $7.67, Oncolytics Biotech has a potential upside of 214.2% from its current price of $2.44. AnalystRatingsNetwork 6/1/20, 05:33 AM Oncolytics Biotech's buy rating reiterated at Canaccord Genuity. $7.00 PT. marketbeat.com/stocks/NASDA... $ONCY saxy4u Bullish 5/31/20, 10:24 PM $ONCY going to suck to cover all that short volume!!!! 65%!!!!! Anyone say 🚀? Where are you Elon? shortvolumes 5/31/20, 10:14 PM 2020-05-29 Short sale volume (not short interest) for $ONCY is 65%. shortvolumes.com/?t=ONCY via @shortvolumes Diet Bullish 5/31/20, 04:25 PM $ONCY $GMDA $AVEO $ADMA Given the red market tomorrow, no better industry to put your money in than healthcare Reneejordan001 5/31/20, 01:53 PM $ONCY Now this is where pelareorep will come in handy in conjunction with Ibrance! fool.com/investing/2020/05/... saxy4u Bullish 5/31/20, 12:14 PM $ONCY here is a left field fly ball. Keytruda/ Pelareorep advanced lung cancer, Wuhan University CT-I trial! ???????????” Our results showed that, among the multiple chemotherapy-based combination therapy strategies, chemotherapy combined with immunotherapy is the best choice for patients with advanced lung cancer, and pembrolizumab combined with chemotherapy has the best effect.” preprints.org/ Not Peer-reviewed posted May 31:2020 Bobhansson04 Bullish 5/31/20, 11:33 AM $ONCY Can someone share the overview with overview of buyouts of Onco’s peers? I’ve seen it in here but cannot find it myself. Thanks! Ulconindicator 5/31/20, 10:55 AM $ONCY A COVID mention. jewishlifenews.com/uncatego... romura1 5/31/20, 10:45 AM $ONCY Canadafan14 5/31/20, 10:45 AM $ONCY Time for some, brief & to the point ONC(Y) education. ONC has a great investor presentation web site. Asa minimum please go there & educate your self. Some ( not all) post on here with total lies. AKA bashing while pretending to be bullish. …while actually shorting. Point #2: ONC is in co- development trials with Pfizer, Roche,Merck & B.M.S They have as of last 6 months identified 2 biomarkers, and recent proof of concept, with 2 new entry level studies. Point #3,They have approval to start & are working towards the best case possible to start Phase 3 trial with MBc They already have a paying partner with Adlai Nortye, to market palareorep, once approved. There are about 4 analysts with buy to strong buy ratings with an average price of $7.00 In the open market the price does and always will go up and go down. As I started, go the the oncolyticsbiotech.com/ and educate yourself. Ldry Bullish 5/31/20, 09:34 AM $ONCY Analysts upgrade to strong buy. Low $8 high$10 US. 94/100 grade